阿博
commented on
阿博
liked
Genting's stock has surged 25% since last December and gained 8.66% year-to-date (YTD), closing at RM5.02 on Tuesday. For FY2023, Genting posted a net profit of RM929.2 million, rebounding from an RM299.9 million net loss last year.
Analysts remain bullish on $GENTING(3182.MY$'s prospects, citing multiple positive factors. HLIB raised its FY24-25 projection on Genting by 3-6% as it raised its revenue assumption and projected a narro...
Analysts remain bullish on $GENTING(3182.MY$'s prospects, citing multiple positive factors. HLIB raised its FY24-25 projection on Genting by 3-6% as it raised its revenue assumption and projected a narro...
34
#GENTING BERHAD
YTL, SUNWAY OR ANOTHER SUPPORT CONGLOMERATE
YTL, SUNWAY OR ANOTHER SUPPORT CONGLOMERATE
Translated
#云顶持股20% of TaurX: New Alzheimer's Drug Data Shows Continued Efficacy | https://www.klsescreener.com/v2/news/view/1290505
Translated
$GENTING(3182.MY$ The market opens tomorrow for $6!
Professor Alistair Burns, Professor Emeritus of Geriatric Psychiatry at the University of Manchester and former National Clinical Director of Dementia in England, said: “We have reached an exciting time in the field of Alzheimer's treatment. After a generation without new treatments, we are about to have a range of new treatments, including oral therapies targeting tau protein, which have real potential to slow the progression of the disease. This is great news for Alzheimer's patients, their families, and caregivers.Two Year Benefit Cognitive Benefits of Hydromethylthionine Mesylate...
Professor Alistair Burns, Professor Emeritus of Geriatric Psychiatry at the University of Manchester and former National Clinical Director of Dementia in England, said: “We have reached an exciting time in the field of Alzheimer's treatment. After a generation without new treatments, we are about to have a range of new treatments, including oral therapies targeting tau protein, which have real potential to slow the progression of the disease. This is great news for Alzheimer's patients, their families, and caregivers.Two Year Benefit Cognitive Benefits of Hydromethylthionine Mesylate...
Translated
4
5
$GENTING(3182.MY$ Five and a half dollars tomorrow
#taurx
#alzheimer's
#分析员目前保持云顶的 “Buy” rating and target price of RM5.73, but investors are encouraged to buy now and make early arrangements.
TaurX will announce the full Phase 3 clinical trial results for HMTM on the 7th of this month at 8:50 p.m. Malaysia time in Lisbon, Portugal. Bank of Malaysia Investment Bank believes that if the relevant drug is finally approved, Genting's target price may soar to RM9.40. Currently, the target price is RM5.73.
#taurx
#alzheimer's
#分析员目前保持云顶的 “Buy” rating and target price of RM5.73, but investors are encouraged to buy now and make early arrangements.
TaurX will announce the full Phase 3 clinical trial results for HMTM on the 7th of this month at 8:50 p.m. Malaysia time in Lisbon, Portugal. Bank of Malaysia Investment Bank believes that if the relevant drug is finally approved, Genting's target price may soar to RM9.40. Currently, the target price is RM5.73.
Translated
5
阿博 : Thai forest is no good